Measuring the Effect of ITPP on Tumor Hypoxia with
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Day 0: Prepare and shave 5 mice (6 weeks of age) around the 4th right inguinal nipple 3 days before implantation
Day 3: Subcutaneous injection of 4T1 tumor cell line mammary epithelial tumor cells into the mammary fat pad
Day 12: Baseline MSOT imaging 9 days post-implantation (tumors are around 4-5 mm in diameter)
Day 13: MSOT imaging 10 days post-implantation and 3 hours post-injection (ITPP or phosphate buffered saline control)
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Figure 1: Hypoxia in tumors leads to poor response to T cell-based immunotherapy. A hypoxic tumor microenvironment promotes
tumor growth and proliferation. Various factors contribute to hypoxic tumor microenvironment leading to decreased T cell extravasation and
increased T cell apoptosis.1 Abbreviations: CAM, cell adhesion molecules; VEGF, vascular endothelial growth factor; FGF, fibroblast growth
factor; IL, interleukin; CAF, cancer-associated fibroblast; HIF-1α, hypoxia-inducible factor 1α; MDSC, myeloid-derived suppressor cell; TAM,
tumor-associated macrophage; Treg, regulatory T cell.

Hypoxia within solid tumors creates an environment that promotes tumor growth and
development. Hypoxia induces HIF-1α, which increases tumor angiogenesis. Tumor
angiogenesis then generates abnormal vasculature leading to decreased expression of
vascular adhesion molecules, thus decreasing T cell recruitment and extravasation.2 Hypoxia
also induces an anti-inflammatory, immunosuppressive, M2 phenotype in macrophages that
further hinders anti-tumor T cell function and trafficking. In addition, HIF-1α induces T cell
apoptosis via Fas to Fas ligand interactions. Because T cells are hindered from entering the
tumor environment, the tumors are resistant to T cell-based cancer immunotherapies, thus
leading to poor prognoses.2

Figure 3: The use of MSOT to determine the level of oxygenation within the tumor environment. Mouse is given 21% medical grade air. MSOT emits light at different wavelengths (700, 730, 760, 800, 850, and 875 nm). The light is
absorbed by oxyhemoglobin and deoxyhemoglobin, which undergoes thermoelastic expansion, also known as the optoacoustic effect. The thermoelastic expansion results in ultrasound waves. Images are created from the ultrasound
waves. Spectral unmixing of the tumor image separates the oxyhemoglobin and deoxyhemoglobin absorption. %sO2 is calculated, and the overall oxygenation of the tissue is obtained. The oxygenation levels from the baseline MSOT
scan and post-ITPP injection scan are obtained and compared to determine if ITPP improved oxygenation.

Results:
The study of tumor reoxygenation with ITPP as monitored with MSOT is ongoing (Figure 4). As an example of expected results, Figures
5 and 6 demonstrate a related project that shows the classification of normoxic (Su86.86), mildly hypoxic (MIA PaCa-2) and very hypoxic
(Colo357) tumors.
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Myo-inositol trispyrophosphate (ITPP) changes oxygen unloading from hemoglobin, thus
"#$!
changes %sO2.3 %sO! = "#%"#$
, where HbO2 is oxyhemoglobin and Hb is deoxyhemoglobin.
!

ITPP also activates endothelial Phosphatase-and-Tensin-homologue (PTEN), thus inhibiting
tumor cell growth and proliferation.4
Multi Spectral Optoacoustic Tomography (MSOT) measures deoxyhemoglobin and
oxyhemoglobin at distinct wavelengths.5 MSOT provides a non-invasive way to measure tumor
hypoxia to determine response to cancer therapies. Compared to other imaging techniques
like magnetic resonance imaging, MSOT is quick, patient-friendly and decreases radiation
exposure to patients.
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Figure 4: Baseline MSOT image (left) of the 4T1 mammary epithelial tumor on the 4th right inguinal
nipple before ITPP injection. Post-injection MSOT image (right) of the 4T1 mammary epithelial tumor
on the 4th right inguinal nipple 3 hours post-ITPP injection. The tumor was about 4 to 5 millimeters in
diameter. The legs and spinal cord were used as landmarks to find the tumor before the scan. After
completing the scans, both sets of the tumor scans (baseline and post-injection) were spectrally unmixed
to separate the oxyhemoglobin and deoxyhemoglobin absorption.
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Figure 5: %sO2 signals from Su86.86 (green), MIA
PaCa-2 (blue), and Colo357 (red) tumor models on
21% O2 medical grade air. At constant temperature. The
MSOT showed a consistent measures, confirming the
mouse was stable when breathing 21% O2.

Figure 6: The average value and standard deviation
of %sO2 of 10 mice with Su86.86, 10 mice with MIA
PaCa-2, and 10 mice with Colo357, all breathing 21%
O2. Su86.86, MIA PaCa-2, and Colo357 are pancreatic
tumor model cell lines obtained from patients and
conditioned to grow in immunocompromised mice.

Conclusions:
MSOT has shown to accurately determine the oxygenation of in the Su86.86, MIA PaCa-2, Colo357 pancreatic tumor models in mice.
MSOT has the potential to determine changes in tumoral oxygenation in response to ITPP.

Future Directions:
MSOT will continue to be utilized to determine the %sO2 of tumors. MSOT is currently being tested within the clinical setting on human
patients. To continue investigating if ITPP improves the effectiveness of checkpoint blockade, further studies will investigate the effect of
ITPP on tumor size and the effect of ITPP on immunogenicity. If ITPP shows to reduce tumor size and increase immunogenicity, the
ITPP injection will be effective in improving responses to checkpoint blockade immunotherapy.

Responsible Conduct of Research:
The MD Anderson PI was responsible for maintaining documents and approvals for all modifications in the protocol. All mice were
handled in compliance with regulations set by MD Anderson's ethics review board (IACUC).
Figure 2: The wavelengths absorbed by various media. MSOT can
be used to detect the oxygenation of tumors because oxyhemoglobin
(HbO2) and deoxyhemoglobin (HbR) absorb distinct wavelengths of light.
Figure courtesy of iThera Medical, Inc.
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